Indication aclasta
WebVolwassenen (incl. ouderen) Aclasta: eenmalige i.v.-infusie in > 15 min: 5 mg in 100 ml waterige oplossing. Tevens dagelijks: elementair calcium (> 500 mg 2×/dag gedurende > 10 dagen) en vitamine D. Herbehandeling na een periode van remissie: na een interval van één jaar of langer een aanvullende i.v.-infusie in > 15 min van 5 mg in 100 ml waterige … Web16 jan. 2024 · Aclasta is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men. It is used in patients who …
Indication aclasta
Did you know?
WebAclasta® no debe usarse en pacientes con disfunción renal (depuración de creatinina ®, debe calcularse la depuración de creatinina del paciente (p. ej., mediante la fórmula de Cockroft Gault). Los pacientes deben estar adecuadamente hidratados antes y después de la administración de Aclasta®; esto es particularmente importante en los ancianos y los … Web1 apr. 2009 · Zoledronic acid 4 mg (usually infused every 3–4 weeks) is used to treat hypercalcaemia and to prevent skeletal-related events in people with malignancies. 4. Zoledronic acid 5 mg infusion is TGA approved for treating osteoporosis in postmenopausal women, and in women and men aged over 50 years with a minimal-trauma hip fracture. 3.
WebCosa contiene Aclasta. Il principio attivo è l'acido zoledronico. Ogni flacone da 100 ml di soluzione contiene 5 mg di acido zoledronico (come monoidrato). Un ml di soluzione contiene 0,05 mg di acido zoledronico (come monoidrato). Gli altri componenti sono mannitolo, sodio citrato e acqua per preparazioni iniettabili. Web16 feb. 2024 · Warnings. Do not use if you are pregnant. Use effective birth control, and ask your doctor how long to prevent pregnancy after you stop using zoledronic acid.. Zoledronic acid can cause serious kidney problems, especially if you are dehydrated, if you take diuretic medicine, or if you already have kidney disease. Call your doctor if you …
WebAclasta is not recommended for use in children and adolescents below 18 years of age due to a lack of data on safety and efficacy. Method of Administration Aclasta (5 mg in 100 mL ready to infuse solution) is administered intravenously via a vented infusion line, given at a constant infusion rate. The infusion time must not be less than 15 minutes. Web28 jun. 2012 · ACLASTA est un bisphosphonate administré une fois par an en perfusion IV. Sa nouvelle indication est le traitement de l’ostéoporose associée à une corticothérapie …
http://www.huisarts.be/attestfr/Aclasta%20FR.pdf
WebIndications/Uses Osteoporosis in men & postmenopausal women at increased risk of fracture, including those w/ recent low-trauma hip fracture. Paget's disease of bone. Treatment & prevention of glucocorticoid-induced osteoporosis. Prevention of postmenopausal osteoporosis. Click to view Aclasta detailed prescribing information lying in state - ukWeb1. Overview. Bisphosphonates are widely used to treat and prevent bone-related conditions. They act by inhibiting osteoclast activity and bone resorption. Individual bisphosphonates have different ... kingswood activity centre west runtonWebPublic Summary Document. Product: Zoledronic Acid, solution for I.V. infusion, 5 mg (as monohydrate) in 100 mL, Aclasta ® Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: November 2012 1. Purpose of Application. To extend the current Authority Required (Streamlined) listing for the treatment as the sole PBS … lying in state 意味WebACLASTA est indiqué dans le traitement de : Ostéoporose post-ménopausique, Ostéoporose masculine, Ostéoporose ass. Toutes les infos sur ce médicament lying-in-state 意味WebIndications Caractéristiques Génériques Présentations Aclasta est un médicament de la famille des Biphosphonates. Il est utilisé pour les traitements ou en cas d'apparition des … lying in state streamWebZoledronic acid (Reclast®, Aclasta®) is an intravenous, highly potent aminobisphosphonate approved worldwide, including in the USA, EU and Japan for use in patients with primary or secondary osteoporosis or low bone mass (approved indications vary between countries). kingswood aluminium great yarmouthWebCockroft-Gault avant chaque traitement par Aclasta o La contre-indication chez les patients présentant une clairance de la créatinine <35 ml/min o La contre-indication chez la femme enceinte ou qui allaite en raison du potentiel tératogène o La nécessité de s’assurer d’une hydratation adéquate de la patiente lying-in-state 中文